GESALO to boost Saudi-German trade ties

From left, Sarah Ayed Al-Ayed, board member, JCCI; Holger Ziegeler, German consul general; Mohammed Yousuf Naghi, JCCI chairman; Dr. Dalia Samra-Rohte, delegate of GESALO; Dr. Martin Wansleben CEO, Association of German Chambers of Industry and Commerce; Imad Mohammed Hashem, secretary-general of JCCI; Khaled Al-Juffali, chairman, E.A. Juffali and Brothers; and Dina Hasan Al-Nahdi, board member, JCCI.
Short Url
Updated 05 February 2020

GESALO to boost Saudi-German trade ties

The Jeddah Chamber of Commerce and Industry (JCCI) hosted the opening of the German-Saudi Liaison Office for Economic Affairs (GESALO), the official representative of German industry in the Kingdom, with aims to enhance the bilateral relationship and promote trade between the two countries. 

Those present on the occasion included CEO of the Association of German Chambers of Industry and Commerce Dr. Martin Wansleben, Delegate of GESALO Dr. Dalia Samra-Rohte, Consul General of Germany in Jeddah Holger Ziegeler, Chairman of the Board of Directors of the JCCI Mohammed bin Yusuf Naghi, Secretary-General Imad bin Muhammad Hashem, and a number of representatives of the Saudi-German business community.

Dr. Samra-Rohte said that a permanent German Desk in Jeddah will play a major role in exploring investment opportunities in both countries and strengthening Saudi-German trade relations throughout the Kingdom, with the support of the main office In Riyadh and the German Desk in the Eastern Province, which will allow GESALO to cover more sectors of the Saudi economy closely, in line with the Kingdom’s Vision 2030.

Dr. Samra-Rohte described the opening of the German office in Jeddah as a milestone for GESALO during a period of great economic development in the Kingdom, expressing her happiness on being able to experience these positive developments. While the city of Jeddah offers a lot, the greatest potential lies within the logistics sector and the advancement in the tourism sector.

Consul General Ziegeler said the German Desk in Jeddah supports joint efforts to strengthen German-Saudi economic relations, as it is an official representation of German industry and trade in Saudi Arabia, and will provide all the information that serves the business community and investment opportunities in different sectors.

GESALO is part of the network of German Chambers of Commerce Abroad (AHKs), which has 140 offices in 92 countries around the world. The German office in the Kingdom has been operating as a nonprofit organization for more than 40 years.

The network of German Chambers of Commerce Abroad is an institution for promoting German foreign trade, and the Association of German Chambers of Industry and Commerce (DIHK) coordinates and develops the network. It is funded by the German Federal Ministry of Economic Affairs and Energy (BMWi).


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.